GoAI
Get started
uniQure N.V. logo

uniQure N.V.

QURE

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$48.37

−$0.52 · -1.06%

Aug 21, 4:00 PM ET

QURE company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

2

Overpriced

Momentum

65

Gaining

Sentiment

62

Bullish

Risk resilience

42

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Industry
Biotechnology
Sector
Healthcare
Headquarters
NL
CEO
Matthew Kapusta
Listed since
Feb 5, 2014
Employees
221

Market position

Day range

Current $48.37

52-week range

Current $48.37

Open
$49.18
Previous close
$48.89
Volume
673.86K
0.35× average
Average volume
1.9M
Average daily volume
Market cap
3.36B USD
Beta
0.94
Market reference 1
50-day average
$42.719
+13.23% above average
200-day average
$27.3991
+76.54% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.83B USD
EV / EBITDA
-15.72×
Earnings yield
-14.46%
Free cash flow yield
-12.93%

Profitability & efficiency

Return on equity
-100.04%
Return on assets
-24.12%
Return on invested capital
-24.53%

Financial health

Current ratio
10.43×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends301%-516%-1334%-2151%Gross margin, FY2021: 95.23%Gross margin, FY2022: 96.86%Gross margin, FY2023: 13.98%Gross margin, FY2024: 32.42%Gross margin, FY2025: 89.53%Operating margin, FY2021: 59.28%Operating margin, FY2022: -134.44%Operating margin, FY2023: -1785.46%Operating margin, FY2024: -679.58%Operating margin, FY2025: -1166.77%Net margin, FY2021: 62.90%Net margin, FY2022: -119.07%Net margin, FY2023: -1947.09%Net margin, FY2024: -883.35%Net margin, FY2025: -1236.00%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 95.23%. Gross margin FY2022 96.86%. Gross margin FY2023 13.98%. Gross margin FY2024 32.42%. Gross margin FY2025 89.53%. Operating margin FY2021 59.28%. Operating margin FY2022 -134.44%. Operating margin FY2023 -1785.46%. Operating margin FY2024 -679.58%. Operating margin FY2025 -1166.77%. Net margin FY2021 62.90%. Net margin FY2022 -119.07%. Net margin FY2023 -1947.09%. Net margin FY2024 -883.35%. Net margin FY2025 -1236.00%.

Income trends

Revenue

16.1M USD-40.64%

Operating income

−187.83M USD-1.92%

Net income

−198.97M USD+16.94%
Income trends across reported periods607.25M USD274.26M USD−58.73M USD−391.73M USDRevenue, FY2021: 524M USDRevenue, FY2022: 106.48M USDRevenue, FY2023: 15.84M USDRevenue, FY2024: 27.12M USDRevenue, FY2025: 16.1M USDOperating income, FY2021: 310.62M USDOperating income, FY2022: −143.16M USDOperating income, FY2023: −282.87M USDOperating income, FY2024: −184.29M USDOperating income, FY2025: −187.83M USDNet income, FY2021: 329.59M USDNet income, FY2022: −126.79M USDNet income, FY2023: −308.48M USDNet income, FY2024: −239.56M USDNet income, FY2025: −198.97M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 524M USD. Revenue FY2022 106.48M USD. Revenue FY2023 15.84M USD. Revenue FY2024 27.12M USD. Revenue FY2025 16.1M USD. Operating income FY2021 310.62M USD. Operating income FY2022 −143.16M USD. Operating income FY2023 −282.87M USD. Operating income FY2024 −184.29M USD. Operating income FY2025 −187.83M USD. Net income FY2021 329.59M USD. Net income FY2022 −126.79M USD. Net income FY2023 −308.48M USD. Net income FY2024 −239.56M USD. Net income FY2025 −198.97M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue16.1M USD27.12M USD15.84M USD106.48M USD524M USD
Cost of goods sold1.69M USD18.33M USD13.63M USD3.34M USD24.98M USD
Gross profit14.41M USD8.79M USD2.22M USD103.14M USD499.03M USD
Research and development140.67M USD143.78M USD214.86M USD197.59M USD143.55M USD
Selling, general, and administrative65.34M USD50.68M USD73.08M USD54.7M USD56.29M USD
Operating expenses202.24M USD193.09M USD285.09M USD246.3M USD188.41M USD
Interest income16.97M USD21.42M USD19.56M USD609K USD162K USD
Interest expense61.99M USD63.74M USD41.56M USD11.7M USD7.47M USD
Depreciation and amortization14.76M USD12.64M USD11.9M USD8.54M USD7.3M USD
Operating income−187.83M USD−184.29M USD−282.87M USD−143.16M USD310.62M USD
Net income−198.97M USD−239.56M USD−308.48M USD−126.79M USD329.59M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$57.50

18.88% upside
Past 12 months12-month forecastHigh $80.00Average $57.50Low $28.00

Rating distribution

38 ratings
Strong buy13%
Buy3284%
Hold513%
Sell00%
Strong sell00%

QURE news

seekingalpha.com

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring…

Read source
zacks.com

QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130 and a cash runway into 2030 keep its pipeline in focus.

Read source
247wallst.com

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Bloom Energy, Dave, Fiverr, Humana, Las Vegas Sands, Lemonade, Procter & Gamble, SK hynix, Wix.com, and More

Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise, and a brutal semiconductor selloff forced some major rating reversals across insurance, gaming, tech, and energy…

Read source
seekingalpha.com

uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript

uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

uniQure Q2 Earnings Call Highlights

uniQure NASDAQ: QURE said it has aligned with the U.S. Food and Drug Administration on a potential accelerated-approval pathway for AMT-130, its investigational gene therapy for Huntington's disease, and remains on track…

Read source
zacks.com

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure (QURE) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $0.69 per share a year ago.

Read source

QURE peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding QURE

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
122.77M
Weight
1.08%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
34.18M
Weight
0.04%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
15.87M
Weight
0.07%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
First Trust Small Cap Growth AlphaDEX Fund logoFirst Trust Small Cap Growth AlphaDEX FundFYC
Market value
7.93M
Weight
0.56%
AUM
1.42B USD
Expense ratio
0.70%
Price / 1D
$122+0.71%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
6.2M
Weight
0.03%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%
Direxion Daily S&P Biotech Bull 3X Shares logoDirexion Daily S&P Biotech Bull 3X SharesLABU
Market value
4.87M
Weight
0.75%
AUM
645.76M USD
Expense ratio
0.96%
Price / 1D
$317.2+4.03%
State Street SPDR S&P Kensho New Economies Composite ETF logoState Street SPDR S&P Kensho New Economies Composite ETFKOMP
Market value
4.26M
Weight
0.16%
AUM
2.71B USD
Expense ratio
0.20%
Price / 1D
$69.24+0.92%
Invesco Dorsey Wright Healthcare Momentum ETF logoInvesco Dorsey Wright Healthcare Momentum ETFPTH
Market value
4.24M
Weight
1.57%
AUM
273.34M USD
Expense ratio
0.72%
Price / 1D
$62.9761+1.53%

Continue in GoAI

Research QURE

research.disclaimer